Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 7
2020 6
2021 4
2022 2
2023 2
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapeutic targeting of surfaceome heterogeneity in AML.
Bordeleau ME, Audemard É, Métois A, Theret L, Lisi V, Farah A, Spinella JF, Chagraoui J, Moujaber O, Aubert L, Khakipoor B, Mallinger L, Boivin I, Mayotte N, Hajmirza A, Bonneil É, Béliveau F, Pfammatter S, Feghaly A, Boucher G, Gendron P, Thibault P, Barabé F, Lemieux S, Richard-Carpentier G, Hébert J, Lavallée VP, Roux PP, Sauvageau G. Bordeleau ME, et al. Among authors: richard carpentier g. Cell Rep. 2024 Jun 25;43(6):114260. doi: 10.1016/j.celrep.2024.114260. Epub 2024 Jun 4. Cell Rep. 2024. PMID: 38838225 Free article.
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Ganan-Gomez I, et al. Among authors: richard carpentier g. Nat Med. 2022 Mar;28(3):557-567. doi: 10.1038/s41591-022-01696-4. Epub 2022 Mar 3. Nat Med. 2022. PMID: 35241842 Free PMC article.
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Richard-Carpentier G, et al. Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):212-218. doi: 10.1016/j.clml.2019.09.608. Epub 2019 Sep 30. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32035785 Clinical Trial.
Recent Advances in Adult Acute Lymphoblastic Leukemia.
Richard-Carpentier G, Kantarjian H, Jabbour E. Richard-Carpentier G, et al. Curr Hematol Malig Rep. 2019 Apr;14(2):106-118. doi: 10.1007/s11899-019-00503-1. Curr Hematol Malig Rep. 2019. PMID: 30879177 Review.
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.
Davidson MB, Kennedy JA, Capo-Chichi JM, Shi Y, Xu W, Cheung V, Arruda A, Bankar A, Richard-Carpentier G, Chan S, Maze D, Minden MD, Schimmer AD, Schuh AC, Sibai H, Yee K, Tierens A, Viswabandya A, Gupta V. Davidson MB, et al. Among authors: richard carpentier g. Blood Adv. 2024 Mar 12;8(5):1281-1294. doi: 10.1182/bloodadvances.2023011735. Blood Adv. 2024. PMID: 38170760 Free PMC article.
Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase.
Perusini MA, Andrews C, Atenafu EG, Gupta V, Maze D, Schuh AC, Yee KW, Bankar A, Davidson MB, Richard-Carpentier G, Chan SM, Sibai J, Schimmer AD, Minden MD, Sibai H. Perusini MA, et al. Among authors: richard carpentier g. Hematology. 2024 Dec;29(1):2329027. doi: 10.1080/16078454.2024.2329027. Epub 2024 Mar 25. Hematology. 2024. PMID: 38526239 Free article.
Single-agent and combination biologics in acute myeloid leukemia.
Richard-Carpentier G, DiNardo CD. Richard-Carpentier G, et al. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):548-556. doi: 10.1182/hematology.2019000059. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808888 Free PMC article. Review.
Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML.
Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, Henderson J, Shi C, Richard-Carpentier G, Sauvageau G, Baggerly K, Al-Atrash G, Davis RE, Daver N, Zha D, Konopleva M. Herbrich S, et al. Among authors: richard carpentier g. J Immunother Cancer. 2021 Jul;9(7):e002968. doi: 10.1136/jitc-2021-002968. J Immunother Cancer. 2021. PMID: 34326171 Free PMC article.
Impact of secondary-type mutations in NPM1 mutated AML.
Zhou Q, Zhao D, Zarif M, Yeung YWT, Richard-Carpentier G, Chang H. Zhou Q, et al. Among authors: richard carpentier g. Eur J Haematol. 2023 Jul;111(1):165-168. doi: 10.1111/ejh.13979. Epub 2023 May 10. Eur J Haematol. 2023. PMID: 37165755 No abstract available.
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Richard-Carpentier G, et al. Haematologica. 2023 Sep 1;108(9):2331-2342. doi: 10.3324/haematol.2022.282030. Haematologica. 2023. PMID: 36951163 Free PMC article.
27 results